Life Sciences

Holliston medical device maker Harvard Bioscience is set to acquire a Minnesota biomedical firm for $70 million, simultaneous to a $20-million sale of Harvard's subsidiary Denville Scientific.

What's it like to bring a company back to life after near bankruptcy? Jim McGorry, CEO of Holliston biotech Biostage, explains how the company never lost faith.

Holliston-based Biostage announced Wednesday the closing of a $4.2-million private investment primarily with a Chinese investment group and a Connecticut children's hospital.

In order to complete a $4-million deal with a private investor and save the company from insolvency, Holliston biotech Biostage has performed a 20:1 reverse stock split.

RXi Pharmaceuticals, a clinical-stage drug company based in Marlborough, announced positive results from a clinical trial of its lead drug candidate, RXI-109.

Hollistion biotech manufacturer Biostage has notified the U.S. Securities and Exchange Commission its third-quarter report will be late.

After being delisted on NASDAQ last week, Holliston biotech Biostage has laid off 17 of its 24 employees, a 71-percent reduction, the company announced Thursday.

Marlborough medical device manufacturer Boston Scientific has closed on the $300-million purchase of a privately-held California medical device company.

Life sciences analystics technology firm SCIEX announced last week the appointment of Inese Lowenstein as the Framingham-based company's new president.

Holliston-based Biostage Inc. on Monday announced the first implant of its proprietary Cellspan Esophageal Implant in a human patient.